Search

Your search keyword '"Flickinger, John C."' showing total 1,511 results
Start Over Author "Flickinger, John C."
1,511 results on '"Flickinger, John C."'

6. Spinal Meningioma

Author

Mulherkar, Ria, Alan, Nima, Flickinger, John C., Gerszten, Peter C., Chang, Eric L., editor, Brown, Paul D., editor, Lo, Simon S., editor, Sahgal, Arjun, editor, and Suh, John H., editor

Published
2024
Full Text
View/download PDF

9. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways

Author

Milano, Michael T, Grimm, Jimm, Soltys, Scott G, Yorke, Ellen, Moiseenko, Vitali, Tomé, Wolfgang A, Sahgal, Arjun, Xue, Jinyu, Ma, Lijun, Solberg, Timothy D, Kirkpatrick, John P, Constine, Louis S, Flickinger, John C, Marks, Lawrence B, and El Naqa, Issam

Subjects
Cancer, Rare Diseases, Brain Cancer, Neurosciences, Eye Disease and Disorders of Vision, Brain Disorders, Patient Safety, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Eye, Adenoma, Blindness, Cavernous Sinus, Craniopharyngioma, Humans, Maximum Tolerated Dose, Meningeal Neoplasms, Meningioma, Models, Biological, Models, Theoretical, Optic Chiasm, Optic Nerve, Organs at Risk, Pituitary Neoplasms, Radiation Dose Hypofractionation, Radiation Tolerance, Radiosurgery, Radiotherapy Dosage, Re-Irradiation, Skull Base Neoplasms, Visual Acuity, Visual Fields, Other Physical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeDosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation.Methods and materialsEligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION).ResultsThirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in

Published
2021

12. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825

Author

Patil, Nirav, Somasundaram, Eashwar, Waite, Kristin A., Lathia, Justin D., Machtay, Mitchell, Gilbert, Mark R., Connor, James R., Rubin, Joshua B., Berens, Michael E., Buerki, Robin A., Choi, Serah, Sloan, Andrew E., Penas-Prado, Marta, Ashby, Lynn S., Blumenthal, Deborah T., Werner-Wasik, Maria, Hunter, Grant K., Flickinger, John C., Wendland, Merideth M., Panet-Raymond, Valerie, Robins, H. Ian, Pugh, Stephanie L., Mehta, Minesh P., and Barnholtz-Sloan, Jill S.

Published
2021
Full Text
View/download PDF

13. Spinal Metastases

Author

Roy, Souvik, Agarwal, Nitin, Burton, Steven A., Flickinger, John C., Gerszten, Peter, Conti, Alfredo, editor, Romanelli, Pantaleo, editor, Pantelis, Evangelos, editor, Soltys, Scott G., editor, Cho, Young Hyun, editor, and Lim, Michael, editor

Published
2020
Full Text
View/download PDF

23. Altered Fractionation in Radiotherapy of CNS Tumors

Author

Flickinger, John C., Brady, Luther W., Series Editor, Lu, Jiade J., Series Editor, Heilmann, Hans-Peter, Honorary Editor, Molls, Michael, Honorary Editor, Trombetta, Mark, editor, Pignol, Jean-Philippe, editor, and Montemaggi, Paolo, editor

Published
2018
Full Text
View/download PDF

24. Spinal Meningioma

Author

Alan, Nima, Flickinger, John C., Gerszten, Peter Carlos, Chang, Eric L., editor, Brown, Paul D., editor, Lo, Simon S., editor, Sahgal, Arjun, editor, and Suh, John H., editor

Published
2018
Full Text
View/download PDF

25. Vascular Malformation

Author

Flickinger, John C., Kano, Hideyuki, Lunsford, L. Dade, Chang, Eric L., editor, Brown, Paul D., editor, Lo, Simon S., editor, Sahgal, Arjun, editor, and Suh, John H., editor

Published
2018
Full Text
View/download PDF

33. Gamma Knife Radiosurgery

Author

Niranjan, Ajay, Bowden, Greg, Flickinger, John C., Lunsford, L. Dade, Chin, Lawrence S., editor, and Regine, William F., editor

Published
2015
Full Text
View/download PDF

37. Guanylyl Cyclase C Vaccines for Secondary Prevention of Metastatic Colorectal Cancer

Author

Flickinger, John C. and Flickinger, John C.

Abstract

Over the last decade, it has become evident that the immune system can be leveraged in the fight against cancer. Indeed, engaging the immune system through immune checkpoint inhibitor therapy has generated unprecedented results and revolutionized cancer drug development. However, effective therapies for many cancers, such as metastatic colorectal cancer (CRC), are still lacking. In this context, we have developed a vaccine against metastatic CRC for individuals with a high-risk of developing this disease. This vaccine targets the tumor-associated antigen guanylyl cyclase c (GUCY2C, GCC), an antigen that is near universally expressed in CRC. A phase I clinical trial testing an adenovirus-based GUCY2C vaccine (Ad5-GUCY2C-PADRE) recently demonstrated the ability to safely induce GUCY2C-specific immune responses in patients. While promising, this trial also indicated that the vaccine is hindered in two capacities. The trial showed that 1) some patients possess pre-existing antibodies that neutralize the adenovirus vaccine vector and prevent the induction of GUCY2C-specific immune responses and 2) many patients fail to mount CD4+ T-cell responses to the CD4+ helper T-cell epitope, PADRE, which is necessary for effective GUCY2C-specific immune responses. Here, we evaluate a novel GUCY2C immunization regimen utilizing the chimeric adenovirus Ad5.F35 and the bacterium Listeria monocytogenes (Lm) as vaccine vectors. We demonstrate that this combination induces potent antitumor immunity and is not limited by pre-existing Ad5 or Lm immunity. Moreover, through defining the utility of this vaccination regimen, we uncover novel findings concerning the role of CD4+ helper T-cells during CD8+ T-cell responses and reveal limitations of the popular vaccine vector, Lm. These studies carry implications for the design of GUCY2C vaccines as well as designs for vaccines targeting other cancer or infectious disease antigens.

Published
2023

47. Gamma Knife Radiosurgery

Author

Niranjan, Ajay, Sirin, Sait, Flickinger, John C., Maitz, Ann, Kondziolka, Douglas, Lunsford, L. Dade, Chin, Lawrence S., editor, and Regine, William F., editor

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results